Incidence and management of chylothorax after Ivor Lewis esophagectomy for cancer of the esophagus

Sebastian Brinkmann, MD, Wolfgang Schroeder, MD, Kristina Junggeburth, MS, Christian A. Gutschow, MD, Marc Bludau, MD, Arnulf H. Hoelscher, MD, and Jessica M. Leers, MD

ABSTRACT

Objective: Chylothorax is a major complication after esophagectomy. As recent studies refer to heterogeneous patient cohorts and surgical procedures, this study was conducted to report the incidence and evaluate the optimal management of chylous fistula in patients treated with transthoracic esophagectomy and 2-field lymphadenectomy for esophageal cancer.

Methods: From January 2005 to December 2013, a total of 906 patients underwent transthoracic esophageal resection for esophageal carcinoma at our institution. En bloc esophagectomy was performed with routine supradiaphragmatic ligation of the thoracic duct. The incidence of chylothorax, and associated morbidity and mortality, were analyzed, and subsequent therapeutic management was reviewed.

Results: Chylothorax after Ivor Lewis esophagectomy was observed in 17 (1.9%) patients. Fifteen patients required surgical intervention with rethoracotomy and repeat duct ligation. Thoracic duct ligation was successful in all patients. Two patients died within 90 days after primary esophageal resection. The median time between initial tumor resection and rethoracotomy was 13 days. Average daily chest-tube output at time of reoperation was 1900 mL. In 2 patients, pleural effusion did not exceed 1000 mL per day. In these cases, conservative management with additional thoracic drainage and total parenteral nutrition led to complete resolution of chylous fistula.

Conclusions: Occurrence of chylothorax after prophylactic thoracic duct ligation during transthoracic esophagectomy for esophageal cancer is rare. In patients with high-output chylous fistula, an early rethoracotomy with repeat ligation of the thoracic duct is safe and helps to shorten recovery time. In cases of low-volume drainage, a conservative approach is feasible. (J Thorac Cardiovasc Surg 2016;151:1398-404)

Chylothorax after transthoracic esophagectomy (TTE) for esophageal carcinoma is a rare event, with a reported incidence of 1% to 9%. However, this postoperative complication is associated with considerable morbidity, particularly from pneumonia with respiratory failure. In addition, recent studies report mortality rates of as high as 20%.

To avoid chylothorax, several suggested approaches for thoracic duct surgery remain a topic of discussion. Although some esophageal surgeons advocate for routine supradiaphragmatic ligation of the thoracic duct, other experts recommend that dissection of the thoracic duct not be included as a standard procedure during TTE.

In cases of a postoperative chylothorax, the optimal clinical management remains unclear. Therapeutic strategies include the following: conservative management, with total

Central Message
Routine thoracic duct ligation leads to a low rate of chylothorax; in cases of chylothorax, early repeat ligation is recommended.

Perspective
Chylothorax is rare after prophylactic thoracic duct ligation, as part of Ivor Lewis esophagectomy for esophageal cancer. With high-output chylous fistula, early rethoracotomy with repeat ligation of the thoracic duct is recommended. In cases of low-volume drainage of <10 mL/kg body weight, a conservative approach is feasible.

See Editorial Commentary page 1405.
Clinical observation of quantity and quality of chest drain output.

During the postoperative course, the diagnosis of chylothorax was based on pleural fluid analysis, which revealed an increased lymphocyte count and triglyceride levels.

Postoperative Management

Chest tubes were routinely removed when output was <200 mL per day. During the postoperative course, the diagnosis of chylothorax was based on clinical observation of quantity and quality of chest drain output.

Abbreviation and Acronym

TTE = transthoracic esophagectomy

Parenteral nutrition or medium-chain triglyceride diets, use of somatostatin and octreotide, lymphangiography and percutaneous embolization of the thoracic duct, and surgical intervention with talc pleurodesis, pleurectomy, or repeat ligation of the thoracic duct. A review of the literature reveals that we still do not know how to determine which patients can be managed conservatively and which require surgical intervention. In this context, the timing of reoperation remains incompletely specified. This retrospective analysis summarizes the experience of a high-volume center for esophageal surgery and aims to draw conclusions on the optimal clinical management of chylothorax after TTE for cancer.

METHODS

Patients

From January 2005 to December 2013, a total of 936 patients underwent esophageal resection at the Department of General, Visceral and Cancer Surgery of the University of Cologne. Only patients treated with curative intention for esophageal cancer who had an en bloc TTE with intrathoracic reconstruction (an Ivor Lewis procedure) were included for further analysis. Patients who received a transhiatal or transthoracic resection with cervical reconstruction, or patients with esophagogastrectomy and colonic interposition were excluded. The retrospective study was approved by the Institutional Review Board of the University of Cologne.

Operative Procedure

The oncological staging consisted of a standardized workup, including endoscopy, endoluminal ultrasound, and computed tomography. Patients who had locally advanced carcinomas (uT3) received neoadjuvant radiochemotherapy up to 41.4 Gy, and one of the following: 5-fluorouracil and cisplatin, prior to 2011; carboplatin and paclitaxel (CROSS protocol) since 2012; or perioperative chemotherapy, according to standardized protocols (FLOT [fluorouracil, leucovorin, oxaliplatin, and docetaxel] or MAGIC [Medical Research Council adjuvant gastric infusional chemotherapy]).

After laparoscopic or open gastric mobilization, a right-sided anterolateral thoracotomy was performed for en bloc esophageal resection and extended 2-field lymphadenectomy. The surgical procedure consisted of a routine prophylactic dissection of the thoracic duct, which was identified in its supradiaphragmatic anatomical position, next to the azygos vein, running parallel to the thoracic aorta. The duct, and its adjacent connective tissue, was dissected between 2 Overholt (Aesculap, Inc, Center Valley, Pa) clamps. Next, the caudal portion was closed, using a nonabsorbable suture of size 0 (Ethibond, Ethicon, Inc, Somerville, NJ). The upper thoracic duct was resected as part of the en bloc dissection. The complete technique of laparoscopic or open mobilization of the stomach and TTE with 2-field lymphadenectomy is described in detail elsewhere.

Postoperative Management

Chest tubes were routinely removed when output was <200 mL per day. During the postoperative course, the diagnosis of chylothorax was based on clinical observation of quantity and quality of chest drain output. Chylothorax was diagnosed most often after the onset of oral intake, which routinely started 7 days after esophagectomy. At this time, the initial chest tubes were still in place in most cases. A high-output pleural effusion and an associated change in quality of the pleural fluid, from serous to milky yellowish, led to diagnosis. Whenever diagnosis of a chylothorax was questionable, a provocation test, with oral intake of 200 mL of cream, led to confirmation of diagnosis. Chest-tube output is presented as daily rate (mL), and ratio of drainage to body weight (mL/kg body weight).

In all cases, a primarily conservative approach was initiated for at least 2 days. Conservative management of thoracic duct injury consisted of total parenteral nutrition, and if necessary, an additional pleural drainage. If daily chest-tube output did not decrease, early surgical management was pursued. In these cases, the patient received 200 mL of cream the evening before the operation, to facilitate identification of the injured duct during rethoracotomy. Here, via a right-sided thoracotomy, pleural adhesiolysis and partial mobilization of the gastric tube was performed, to visualize the thoracic aorta in the posterior mediastinum. After identification of the leaking duct on the distal aorta, a supra-diaphragmatic suture between the diaphragm and the previous ligation was performed, using another nonabsorbable suture of size 0 (Ethibond). Reoperation was finished by an extensive lavage of the pleural cavity with saline, with the chest tube in place.

Data Collection

Data for all patients were routinely documented in a database for patients who have esophageal cancer. In the study population, data collection included patient characteristics and demographics, tumor characteristics, histopathologic parameters, neoadjuvant therapy, and type of surgery. Length of hospital stay, postoperative morbidity, and in-hospital mortality were recorded, and postoperative complications were analyzed. Preoperative albumin levels were determined 1 day before esophagectomy. The reported postoperative albumin levels represented the minimum of daily measurements in the postoperative course. Daily chest-tube output was documented, and for each patient, the average output per day was calculated. In addition, we documented daily chest-tube output in 34 randomly selected patients who did not have chylothorax (ratio: 2 to 1), as performed by Shah and colleagues. We defined 3 groups, based on chest-tube output as a ratio of drainage volume and body weight (mL/kg): low = <10; medium = 10-20; and high = 20.

All data were collected using Excel 2013 (Microsoft Corporation, Redmond, Wash). Statistical analysis was performed using SPSS 22.0 software (SPSS, Inc, Chicago, Ill). Analyses were based on descriptive means and median. The Student t test was used to describe differences between groups. To evaluate additional risk factors for postoperative chylothorax, we performed a multivariate analysis as logistic regression analysis, with backward elimination of nonsignificant factors (P > .10).

RESULTS

According to the inclusion criteria, the final study population consisted of 906 patients. The study group consisted of 143 women and 670 men, with a median age of 61.9 (range: 29-92) years. A total of 484 (53.4%) patients had esophageal adenocarcinoma; 422 (46.6%) had squamous cell carcinoma of the esophagus. According to clinical staging, 552 (60.9%) patients with cT3/4 carcinomas received neoadjuvant radiochemotherapy or chemotherapy. Chylothorax after esophagectomy was identified in 17 (1.9%) patients. The study group consisted of 4 women and 13 men, with a median age of 68.7 (range: 44-80) years. A total of 12 (70.6%) patients had adenocarcinoma. Eleven (64.7%) patients received neoadjuvant chemotherapy.
radiochemotherapy. All tumors were located in the middle (n = 7) or lower (n = 10) third of the esophagus. Tumor-free margins of resection were achieved in all patients. Further details regarding patients and tumor characteristics are shown in Table 1, and data on comorbidities and postoperative complications in Table 2.

Chest-tube output of >1000 mL per day led to the diagnosis of chylothorax in all but one case, in which chest-tube output was <1000 mL, but noticeably yellowish. A provocation test with cream confirmed the diagnosis in 8 patients. Chest-tube output as a ratio of drainage volume and body weight (mL/kg) was used to define 3 groups of patients in our study population (Figure 1). In both patients who had a ratio of <10 mL/kg (low-output group), conservative treatment was successful. The time interval between placement and removal of the initial pleural chest tube was 4 and 17 days, respectively. Neither patient had other major complications during their hospital stay. Postoperative hospital stay was increased to 26 and 34 days, respectively. The median chest-tube output during the first 10 postoperative days, for all 17 patients, was divided into 3 groups (low, medium, and high) (Figure 2). A comparison of the 24-hour chest-tube output of patients with versus without chylothorax, on each of the first 10 days after primary resection, showed that the median daily chest-tube output was significantly higher in patients who had the latter diagnosis of chylothorax, compared with the control group (1738 vs 325 mL per day; P < .01) (Figure 3). A total of 4 (23.5%) patients had chest-tube output between 10 and 20 mL/kg (medium-output group). In these patients, the initial postoperative course was uneventful, and the chest tube was routinely removed with low output. Because of pleural effusion on radiograph, a second chest tube was placed, and the fluid was suspicious for chyle. The time from esophagectomy to repeat thoracic

**TABLE 1.** Demographics and characteristics of 17 patients who had chylothorax after transthoracic esophagectomy and routine thoracic duct ligation

<table>
<thead>
<tr>
<th>Preoperative characteristics</th>
<th>n (%) or median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, male</td>
<td>13 (76.5)</td>
</tr>
<tr>
<td>Age (y)</td>
<td>68.7 (44-80)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.4 (18-34)</td>
</tr>
<tr>
<td>&lt;18.5&lt;15</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>&gt;18.5&lt;25</td>
<td>12 (70.6)</td>
</tr>
<tr>
<td>&gt;25</td>
<td>4 (23.5)</td>
</tr>
<tr>
<td>ASA category</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>2</td>
<td>11 (64.7)</td>
</tr>
<tr>
<td>3</td>
<td>4 (23.5)</td>
</tr>
<tr>
<td>4</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>History of tobacco use</td>
<td>10 (58.8)</td>
</tr>
<tr>
<td>Active smoker</td>
<td>7 (41.2)</td>
</tr>
<tr>
<td>Neoadjuvant radiochemotherapy</td>
<td>11 (64.7)</td>
</tr>
<tr>
<td>Tumor-specific variables</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>5 (29.4)</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>12 (70.6)</td>
</tr>
<tr>
<td>Locally advanced tumors (pT3/T4)</td>
<td>7 (41.2)</td>
</tr>
<tr>
<td>Number of lymph nodes removed</td>
<td>27 (9-41)</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td>8 (47.1)</td>
</tr>
<tr>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>Middle third</td>
<td>10 (58.8)</td>
</tr>
<tr>
<td>Lower third</td>
<td>7 (41.2)</td>
</tr>
</tbody>
</table>

IQR, Interquartile range; BMI, body mass index; ASA, American Society of Anesthesiologists; y, patient with neoadjuvant therapy.

**TABLE 2.** Comorbidities and complications in 17 patients who had chylothorax

<table>
<thead>
<tr>
<th>Comorbidities and complications</th>
<th>n (%) or mean (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comorbid conditions</td>
<td>12 (70.6)</td>
</tr>
<tr>
<td>COPD/Asthma</td>
<td>6 (35.3)</td>
</tr>
<tr>
<td>Previous pulmonary embolism</td>
<td>2 (11.8)</td>
</tr>
<tr>
<td>Previous chest surgery</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>9 (52.9)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>Serum albumin status (g/L), mean (range)</td>
<td></td>
</tr>
<tr>
<td>Preoperative</td>
<td>38 (34-47)</td>
</tr>
<tr>
<td>Postoperative</td>
<td>22.0 (16.3-31.2)</td>
</tr>
<tr>
<td>Loss</td>
<td>15.3 (6.8-25.8)</td>
</tr>
<tr>
<td>Major postoperative complications</td>
<td>10 (58.8)</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>7 (41.2)</td>
</tr>
<tr>
<td>Tracheotomy</td>
<td>3 (17.6)</td>
</tr>
<tr>
<td>Acute kidney failure*</td>
<td>5 (29.4)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>5 (29.4)</td>
</tr>
</tbody>
</table>

duct ligation was prolonged (29 days; range: 13-45), compared with the time (13 days; range: 4-23) for the 11 patients of the high-output group (pleural effusion >20 mL/kg).

Repeat ligation of the thoracic duct was successful in 14 (93.3%) patients. A single patient required another trans-thoracic duct ligation 53 days after initial esophagectomy and 18 days after rethoracotomy (Table 3). Three (17.6%) patients developed an anastomotic leakage, which was diagnosed before chylothorax in all cases, and none of them developed further major complications during their postoperative course.

None of the patients died within the first 30 days. Two patients died within 90 days, giving an in-hospital mortality of 11.8%. One patient died from sepsis related to a fulminant Klebsiella pneumonia infection 39 days after repeat thoracic duct ligation. The second patient developed sepsis of unknown origin that rapidly led to multiorgan failure 19 days after operative treatment for chylothorax.

Statistical Analysis
In the multivariate analysis, no significant risk factors were identified for chylothorax. This analysis included the variables gender, age, histology, location of tumor, T-category, N-category, and year of operation.

DISCUSSION
The present study showed a 1.9% incidence of chylothorax after Ivor Lewis esophagectomy. This percentage is at the lower limit of the incidence of 1% to 9% found in other studies. In our opinion, the low incidence of chylothorax in our study is due to the routine supradiaphragmatic ligation of the thoracic duct.

However, the question has not been resolved of whether routine dissection of the thoracic duct is a necessary component of en bloc resection and lymphadenectomy, to improve the oncological prognosis. In a large multicenter trial, not only the nodal status but also the number of lymph nodes removed were demonstrated to be independent factors in survival. In addition, the threshold value for the number of lymph nodes to be removed is easier to achieve when the esophagectomy is performed as an en bloc procedure. Given that preservation of the thoracic duct is technically challenging with an en bloc esophagectomy, many esophageal surgeons recommend that the extension of dissection including the thoracic duct, for oncological reasons. This surgical approach is supported by a morphological study that showed resection of the azygos vein, as part of the en bloc esophagectomy, increased the number of resected lymph nodes. Further, the richness of collateral lymphatic pathways seems to justify thoracic duct ligation, as it can be performed without any serious side effects.

A second question concerning surgical technique is whether the incidence of chylothorax and therefore postoperative morbidity is decreased by routine dissection of the thoracic duct. Hou and colleagues reported an unfavorable overall survival in patients who underwent esophagectomy, mainly via left-sided thoracotomy including routine duct ligation. Furthermore, their retrospective study presented a wide variety of surgical approaches and a noticeably low rate of neoadjuvant therapy. With only 2% of Ivor Lewis esophagectomies, a side-to-side comparison to our data is difficult, as we focused strictly on this right-sided approach. A recent randomized controlled study of 653 patients undergoing right-sided TTE, treated with either routine (n = 325) or no (n = 328) thoracic duct ligation, showed a minimized risk of postoperative chylothorax in patients who had routine dissection and ligation of the thoracic duct during repeat thoracic duct ligation. The second patient developed sepsis of unknown origin that rapidly led to multiorgan failure 19 days after operative treatment for chylothorax.
TTE for cancer. In another study, the incidence of chylothorax in patients who received thoracic duct mass ligation during esophagectomy was 1.2%, compared with 2.1% of patients who had preservation of the thoracic duct. Other studies with a routine thoracic duct ligation report comparable low rates of postoperative chylothorax, of 2.1% and 2.7%. In contrast to these techniques, the Pittsburgh center for esophageal surgery does not support the routine dissection and ligation of the thoracic duct. The reported rate of chylothorax in their series of 862 esophagectomies is 3.8%, which is 2-fold higher than that in our series.

However, chylothorax is a serious complication, associated with substantial morbidity. As the thoracic duct drains approximately 75% of the body’s lymph, thoracic duct injury leads to a particular type of fluid loss that can result in hypovolaemia and respiratory failure. In our cohort, 7 of 17 (41%) patients developed pneumonia or respiratory failure.

| TABLE 3. Postoperative variables of study population, stratified by group according to chest-tube output ratio |
| Variable                                      | Low (n = 2) | Medium (n = 4) | High (n = 11) |
| Time from esophagectomy (d)                   |             |                |               |
| To diagnosis                                  | 18 (9-27)   | —              | —             |
| To repeat duct ligation                       | —           | 29 (13-45)     | 13 (4-23)     |
| To start of oral intake                       | 7.5 (7-8)   | 7.5 (7-8)      | 7 (6-13)      |
| Original chest tube                           | —           | 0              | 11 (100)      |
| Duration (d)                                  | 10.5 (4-17) | 11 (4-25)      | 13 (4-23)     |
| Chest-tube output, median (IQR)              |             |                |               |
| Average (mL/d)                                | 358 (225-490)| 1019 (578-1390)| 1827 (1453-3144) |
| Average (mL/kg body weight)                   | 3.5 (1.9-5.1)| 16.7 (10.7-19.9)| 25.1 (20.5-56.2) |
| Provocation test with oral intake of 200 mL cream | 0          | 1 (25)         | 7 (64)        |
| Major complications                           | 0           | 2              | 5             |
| Respiratory failure and pneumonia             | 0           | 1              | 2             |
| Tracheotomy                                   | 0           | 1              | 2             |
| Acute kidney failure                          | 0           | 1              | 4             |
| Anastomotic leakage                           | 0           | 1              | 2             |
| Necrosis of gastric pull-up                   | 0           | 1              | 0             |
| Length of stay (d)                            |             |                |               |
| Hospital                                      | 30 (26-34)  | 44 (25-90)     | 47 (29-91)    |
| ICU                                           | 4.5 (2-7)   | 5 (2-57)       | 7 (1-64)      |
| In-hospital mortality                         | 0           | 0              | 2 (18.2)      |

Values are n, or n (%), or median (range), unless otherwise indicated. Patient groups according to chest-tube output ratio in mL/kg body weight: low: <10; medium: 10-20; high: >20. IQR, Interquartile range; ICU, intensive care unit. *According to Acute Kidney Injury Work Group (2012) clinical practice guideline.23

| TABLE 4. Literature review of incidence and outcome of postesophagectomy chylothorax |
| First author                  | Year | n   | Approach to esophagectomy | Routine ligation of thoracic duct | Chylothorax | Operative treatment of chylothorax | Mortality |
| Bolger (24)                   | 1991 | 537 | TTE and TH                 | Not performed                      | 2.0         | 27                                   | 45.4      |
| Cerfolio (25)                 | 1996 | 931 | NA                         | NA                                 | 2.9         | 89                                   | 3.7       |
| Dugue (5)                     | 1998 | 850 | TTE                        | 100%                               | 2.7         | 39                                   | 8.7       |
| Alexiou (11)                  | 1998 | 523 | TTE and TH                 | Not performed                      | 4.0         | 19                                   | 23.8      |
| Orringer (26)                 | 1999 | 1085| TH                         | NA                                 | 1.7         | 100                                  | 0.0       |
| Merigliano (10)               | 2000 | 1787| TTE and TH                 | 6%                                 | 1.1         | 79                                   | 5.3       |
| Hulscher (27)                 | 2002 | 220 | TTE and TH                 | 52%                                | 5.9         | NA                                   | NA        |
| Rao (9)                       | 2004 | 552 | TT and TH                  | NA                                 | 2.5         | 50                                   | 28.5      |
| Lai (2)                       | 2011 | 653 | TTE                        | 50%                                | 1.2         | 50                                   | 25.0      |
| Shah (4)                      | 2012 | 892 | TTE and TH                 | Not performed                      | 3.8         | 62                                   | 24.0      |
| Mishra (3)                    | 2012 | 104 | TTE and TH                 | Not performed                      | 8.6         | 100                                  | 22.2      |
| Kranzfelder (28)              | 2013 | 1856| TTE and TH                 | NA                                 | 2.1         | 64                                   | 12.8      |
| Present study                 | 2015 | 906 | TTE                        | 100                                | 1.9         | 88                                   | 11.8      |

Values are %, unless otherwise indicated. TTE, Transthoracic esophagomy; TH, transhiatal esophagectomy; NA, not applicable.
failure with reintubation. These events occurred before re-
thoracotomy performed as a necessary treatment for chylo-
orrhax. The findings are consistent with those of another
study that reported a similar rate of complications due to
postesophagectomy chylothorax. In addition, anastomotic
leakages were diagnosed before the diagnosis of
chylothorax in all cases. Hypovolaemia with a continuous
loss of fat-soluble vitamins, proteins, and electrolytes
causes malnutrition. The resulting T-cell depletion and
loss of immunoglobulins lead to significant impairment of
cell-mediated immunity and humoral responses. As a
consequence, patients are at higher risk for septi-
cemia, with an incidence of sepsis as high as 24%,
comparable to that in our study.

Finally, the optimal management of postoperative chylo-
orrhax is challenging. Conservative treatment is worth the
attempt, but the question of what is optimal timing for
surgical intervention needs to be addressed. As mortality rates
as high as 82% are reported with conservative therapeutic
treatment, the time required to successfully manage chylo-
orrhax is critical. Several authors have suggested
the approach of performing early reoperation, with ligation
of the thoracic duct to reduce the morbidity and mortality
caused by chylous fistula. Some authors recommend
ligation of the thoracic duct when the amount of chylous
drainage exceeds 1000 mL for >7 days.

Measures other than volume alone are needed, but are
currently unreliable. Gibbons and Ahmed pointed out,
and Maldonado confirmed, that the traditionally used
triglyceride levels may be unreliable with patients who
are fasting, especially in the postoperative setting. Merrigan
and colleagues suggested reoperation in patients in whom
chylos loss persists for >5 days, and the chylous leak
produces ≥1000 mL per day. Other studies noted that the
appearance of fluid and volume of chest-drain output alone
lack sensitivity and specificity for detection of chylous
leakage, and they occasionally integrated physical and
biochemical analysis of chyle into their management of
diagnosis.

Until the findings of this study, we used 200 mL of chest-
tube output as the cutoff to remove the chest tube, and we
did not take body weight into account. When we retrospec-
tively evaluated our data, we found that patients’ chest-tube
output per kg body weight correlated well with clinical
outcome and necessary treatment. Three groups of patients
became obvious: high; medium; and low output. In our
experience, the vast majority of cases require surgery with
repeat duct ligation. Yet, conservative treatment was
successful in some cases. Our results indicate that the
threshold for the necessity of surgery is a daily chest-tube
output of >10 mL per kg body weight. In an earlier series
of 23 patients, Dugue and colleagues advocated the same
cutoff of 10 mL/kg daily of chest-tube output as an indicator
for repeat thoracic duct ligation.

In contrast, 11 patients had a daily chylous output of
>20 mL/kg. In these patients, extensive chylous output
led to early surgical treatment after a median of 13 days
postesophagectomy. The initial chest tube was still in place
at the time of repeat thoracic duct ligation in this group of
patients.

A third group of patients need to be addressed sepa-
ately—those in whom the initial chest tube was already
removed at the time of chylothorax diagnosis and
subsequent reoperation. In these cases, the average level
of daily pleural drainage output to body weight was 10 to
20 mL/kg. Possibly, the initial chest-tube drainage was
removed too early for these patients because the diagnosis
of chylothorax was not suspected. The removal
likely would have led to failed initial conservative manage-
ment and a prolonged time until surgical treatment was
initiated. According to the critical level of >10 mL chylous
output per kg body weight, these patients would
have benefited more from an aggressive treatment of
chylothorax, with early repeat duct ligation, than from
an initial conservative therapeutic attempt.

Limitations and Strengths
This retrospective study of a large esophagectomy series
has both strengths and limitations. We present a well
defined patient cohort: All patients underwent a standard-
ized Ivor Lewis esophagectomy for esophageal cancer,
with routine duct ligation. Moreover, in all cases of
chylothorax, surgical therapy was performed via the
transsthoracic route. Other studies often use patient cohorts
that are heterogeneous in regard to primary diagnosis with
various benign and malignant diseases and type of
surgery with transthoracic or transabdominal resection of
the esophagus. In addition, in cases of chylothorax,
surgical therapy has been performed via both the
transsthoracic and transabdominal route. A limitation
of this study is the low number of chylothorax cases, which
makes extensive statistical analyses difficult, along with
drawing evidence-based recommendation for general
clinical management.

CONCLUSIONS
Given its oncological benefit in esophageal cancer pa-
tients, we recommend transthoracic en bloc esophagectomy
with routine thoracic duct ligation. With this approach, the
incidence of chylous thorax is considerably lower, at 1.9%. An
average chest-tube output of >10 mL/kg of body weight
within the first postoperative days should be the trigger
for reoperation. A conservative strategy can be successful
for only a low percentage of cases.

Conflict of Interest Statement
Authors have nothing to disclose with regard to commercial
support.
Thoracic: Esophageal Cancer

References


31. For personal use only. No other uses without permission. Copyright ©2016. Elsevier Inc. All rights reserved.

Key Words: chylothorax, thoracic duct ligation, transthoracic esophagectomy, chest tube, Ivor Lewis